Overview

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Neuraltus Pharmaceuticals, Inc.
Treatments:
Levodopa
Nicotine